



## Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine and Treatment

*- The pre-clinical vaccine was developed by researchers  
at the University of California, San Diego -*

**Lyon, France – September 21, 2011** – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today a research and development collaboration with the University of California, San Diego (UC San Diego) on an immunological approach to acne prevention and treatment targeting the specific neutralization of *Propionibacterium acnes* factors in inflammation.

*Acne vulgaris* (acne) is one of the most common skin diseases worldwide and affects more than 50 million people in the United States alone.<sup>1</sup> The disease has multiple, complex factors and is associated in particular with the Gram-positive anaerobic bacterium *P. acnes* that is a normal member of the human skin microflora.<sup>2</sup> Current treatment of mild forms of acne involves killing *P. acnes* with bactericidal agents such as benzoyl peroxide and oral or topical antibiotics, all of which indiscriminately kill many bacterial species and disrupt the normal balance of the skin microflora.<sup>3</sup> Long-term use of antibiotics also leads to resistant strains of *P. acnes*.<sup>4</sup>

*“This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need,”* according to Elias Zerhouni, M.D., President, Global Research & Development, Sanofi. *“This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease.”*

According to Sanofi Pasteur’s estimates, the annual worldwide market for acne therapeutics is in excess of US \$3 billion. The financial terms of the agreement were not disclosed. The agreement includes a two-year research collaboration with Dr. Chun-Ming Huang and his associates at UC San Diego School of Medicine for further research and development.

### **About Acne**<sup>5,6,7</sup>

Acne is an extremely common multi-factorial skin disease with a prevalence of 80 to 90 percent in adolescents. The disease sometimes continues through the teenage years; eight percent of 25 to 34-year olds and three percent of 35 to 44-year-old people continue to suffer from the disease. Moderate to severe acne occurs in 14 percent of five to 17-year olds and this group is more likely to seek treatment and currently faces an unmet medical need. Acne is considered a chronic disease for a limited life-time period and, although often a simple and self-limited condition, it can result in psychological, physical and social implications.

### **About Sanofi**

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).



Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: [www.sanofipasteur.com](http://www.sanofipasteur.com) or [www.sanofipasteur.us](http://www.sanofipasteur.us)

### **Forward Looking Statements**

*This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

### **References**

1. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol 2004; 22: 360-6.
2. Bojar RA, Holland KT. Acne and *Propionibacterium Acnes*. Clin Dermatol 2004; 22: 375-9.
3. Ochsendorf F. Systematic antibiotic therapy of acne vulgaris. J Dtsch Dermatol Ges 2006; 4: 828-41.
4. Gloor M, Wasik B, Becker A, Hoffer U. Inhibition of lipase activity in antibiotic-resistant *Propionibacterium acnes* strains. Dermatology 2002; 205: 260-4
5. James et al, *Emerging drugs for Acne*, Expert Opinion Drugs, 2009 Informa UK Ltd ISSN 1472-8214
6. A. Thielitz and H Gollnick, *Overview of therapeutic developments for acne*; Expert Rev. Dermatology 4(1), 55-65 (2009)
7. J. Leyden (but supported by a grant from Galderma), *A review of the use of combination therapies for treatment of acne vulgaris*, American academy of dermatology inc.

---

### **Contacts:**

#### **Global Media Relations**

Pascal Barollier  
T. +33-(0)4-37-37-50-38  
[pascal.barollier@sanofipasteur.com](mailto:pascal.barollier@sanofipasteur.com)  
[www.sanofipasteur.com](http://www.sanofipasteur.com)

#### **U.S. Media Relations**

Susan H. Watkins  
T. + 570-957-2563  
[susan.watkins@sanofipasteur.com](mailto:susan.watkins@sanofipasteur.com)  
[www.sanofipasteur.com](http://www.sanofipasteur.com)

#### **Sanofi Investor Relations**

Sebastien Martel  
T. +33 53 77 45 45  
[Sebastien.martel@sanofi.com](mailto:Sebastien.martel@sanofi.com)  
[www.sanofi.com](http://www.sanofi.com)